Quentin V. T.
- Country
- Belgium
- Department
- Hematology
Research Overview
- Efficacy and Safety of REGN7508 for Primary Prophylaxis of Cancer-Associated Thrombosis in Patients with Solid Tumors Undergoing Cancer Treatment
- Phase III Randomized Open‑Label Non‑Inferiority Trial of NXT007 Prophylaxis versus Emicizumab in People with Hemophilia A
- Long-Term Safety Evaluation of Valoctocogene Roxaparvovec in Patients with Severe Hemophilia A Following Prior Gene Therapy with BMN 270
Data & Insights
Has run more than one trial at 21 of 100 partner sites.
Specializations
Hematological Disorders
This investigator specializes in the study of Type 3 Von Willebrand Disease, focusing on developing innovative therapeutic approaches for patients with this rare bleeding disorder.
- Bleeding Disorders Management
- Coagulation Factor Research
- Prophylactic Treatment Strategies
The investigator explores new therapeutic agents for improving patient outcomes in severe bleeding disorders.
Clinical Therapeutics
Research interests center on evaluating prophylactic treatments and their comparative effectiveness against traditional on-demand therapeutic approaches.
- Treatment Efficacy Assessment
- Long-term Safety Monitoring
- Standard of Care Optimization
The investigator's work encompasses comprehensive evaluation of novel therapeutic agents in rare disease management.
Preventive Medicine
Focus areas include the development of preventive treatment protocols for patients with severe bleeding disorders, emphasizing prophylactic approaches.
- Bleeding Prevention Strategies
- Risk Assessment Methods
- Patient Monitoring Protocols
The investigator studies systematic approaches to prevent bleeding episodes in high-risk patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.